Clinical Trial Update: Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating golidocitinib for refractory immune-related hematologic toxicities in patients with advanced lung cancer; the trial status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Golidocitinib (golidocitinib)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: IrAE, Hematologic Disorder | Phase 2 | Status: NOT_YET_RECRUITING